Abstract
The new generation of microbicide candidates is based on the use of antiretroviral (ARV) drugs. The first compounds tested were selected among ARV classes that block the early stages of viral replication cycle, either entry/fusion or reverse transcription. Recently, an additional class of ARVs acting on a later step of viral replication has entered the microbicide pipeline, the protease inhibitors (PIs). This class of ARVs has shown strong potency in highly active antiretroviral therapy (HAART) against human immunodeficiency-1 virus (HIV-1) and lower levels of induced resistance compared to other ARV classes. As candidate microbicides, PIs will have to follow the guiding principles of microbicides being effective, safe, user-friendly and affordable. Hence, aspects including antiviral potency, adverse effects in mucosal tissues, formulation, pharmacology at mucosal sites, emergence of resistance, will have to be considered in the design of a PI-based microbicide. In addition, PIs will have to be tested for their capacity to be used in combination-based microbicides with other ARV classes and in combination with other preventive strategies, such as HIV-1 vaccines. Microbicides containing HIV PIs could also be potentially used against other pathologies specific to the female and/or male genital tract or colorectum.
Keywords: Protease inhibitors, saquinavir, ritonavir, lopinavir, darunavir, microbicides, tissue explants, HIV-1, ARV, HIV-infection
Current HIV Research
Title: Potential Use of Protease Inhibitors as Vaginal and Colorectal Microbicides
Volume: 10 Issue: 1
Author(s): Carolina Herrera and Robin J. Shattock
Affiliation:
Keywords: Protease inhibitors, saquinavir, ritonavir, lopinavir, darunavir, microbicides, tissue explants, HIV-1, ARV, HIV-infection
Abstract: The new generation of microbicide candidates is based on the use of antiretroviral (ARV) drugs. The first compounds tested were selected among ARV classes that block the early stages of viral replication cycle, either entry/fusion or reverse transcription. Recently, an additional class of ARVs acting on a later step of viral replication has entered the microbicide pipeline, the protease inhibitors (PIs). This class of ARVs has shown strong potency in highly active antiretroviral therapy (HAART) against human immunodeficiency-1 virus (HIV-1) and lower levels of induced resistance compared to other ARV classes. As candidate microbicides, PIs will have to follow the guiding principles of microbicides being effective, safe, user-friendly and affordable. Hence, aspects including antiviral potency, adverse effects in mucosal tissues, formulation, pharmacology at mucosal sites, emergence of resistance, will have to be considered in the design of a PI-based microbicide. In addition, PIs will have to be tested for their capacity to be used in combination-based microbicides with other ARV classes and in combination with other preventive strategies, such as HIV-1 vaccines. Microbicides containing HIV PIs could also be potentially used against other pathologies specific to the female and/or male genital tract or colorectum.
Export Options
About this article
Cite this article as:
Herrera Carolina and J. Shattock Robin, Potential Use of Protease Inhibitors as Vaginal and Colorectal Microbicides, Current HIV Research 2012; 10 (1) . https://dx.doi.org/10.2174/157016212799304607
DOI https://dx.doi.org/10.2174/157016212799304607 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs
Current Pharmaceutical Design Insight into Tumor Hypoxia: Radionuclide-based Biomarker as Diagnostic Tools
Current Topics in Medicinal Chemistry Evaluation of Neuroprotective effect of <i>Cassia occidentalis L</i>. against Colchicine Induced Memory Impairment in Wistar Rats
Current Nutraceuticals NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Risk of Cervical Cancer After HPV Vaccination
Current Pharmaceutical Design Treatment Strategies for Cervical Cancer in Older Women: Challenges and Advancements
Current Cancer Therapy Reviews Relationship Between Polymerase Gamma (POLG) Polymorphisms and Antiretroviral Therapy-Induced Lipodystrophy in HIV-1 Infected Patients: A Case-Control Study
Current HIV Research Role of Natural and Synthetic Flavonoids as Potential Aromatase Inhibitors in Breast Cancer: Structure-Activity Relationship Perspective
Anti-Cancer Agents in Medicinal Chemistry Newly Emerging Theranostic Agents for Simultaneous Cancertargeted Imaging and Therapy
Current Medicinal Chemistry Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy
Current Pharmaceutical Design Nucleic Acids as Therapeutic Agents
Current Topics in Medicinal Chemistry Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets Human Papillomavirus Genome based Detection and Typing: A Holistic Molecular Approach
Current Molecular Medicine Nutraceuticals for Promoting Longevity
Current Nutraceuticals Bacterial Infection in Head and Neck Space Regions: A Narrative Review
New Emirates Medical Journal The p53-Mdm2 Pathway: Targets for the Development of New Anticancer Therapeutics
Mini-Reviews in Medicinal Chemistry A Conceptual Model of Psychoneurological Symptom Cluster Variation in Women with Breast Cancer: Bringing Nursing Research to Personalized Medicine
Current Pharmacogenomics and Personalized Medicine 2-Pyrazolines as Biologically Active and Fluorescent Agents, An Overview
Anti-Cancer Agents in Medicinal Chemistry